ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis
June 21, 2021CTI BioPharma Corp.today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L) -
Combining pacritinib with sirolimus-based GvHD prophylaxis may improve efficacy
March 25, 2021Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD). -
CTI Biopharma Announces Phase 3 Pacritinib for COVID-19 Hospitalized Patients
April 30, 2020CTI BioPharma announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. -
CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19
April 28, 2020Will compare pacritinib plus standard of care versus placebo plus standard of care in 358 patients with severe COVID-19. -
CTI BioPharma Completes Enrollment of Phase 2 PAC203 Study of Pacritinib
December 29, 2018CTI BioPharma announced the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The company expects to report the determination of ...... -
CTI BioPharma Corp. Restructures
December 17, 2018CTI BioPharma Corp. is restructuring in an effort to improve efficiencies and reduce costs. As part of the plan, workforce reductions have been implemented that impact approximately 50 percent -
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
March 12, 2018CTI Biopharma Corp.today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology.
Pharma Sources Insight January 2025
